Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.
The Sixth Cambridge Conference on Endocrine and Targeted Manipulation of Breast Cancer was convened in Cambridge, Massachusetts on April 30 and May 1, 2007. The purpose of this multidisciplinary meeting of leaders in clinical and basic research and patient treatment was to assess the most recent data in the field, articulate current best practices, and identify the next steps to advance both patient care and research. Topics included a review of data from major recent and ongoing trials of endocrine treatment in patients with early breast cancer and from studies combining endocrine therapy with other treatment. The current status of breast cancer prevention efforts was examined. Preclinical models of response and resistance, initial efforts to profile tumor response and resistance during endocrine therapy in patients, and new developments in pharmacogenomics were also highlighted. In this article, a synopsis of the key issues discussed, conclusions, and recommendations are summarized; these are presented at greater length in the individual articles and accompanying Open Discussions that comprise the full conference proceedings. In the 2 years since the Fifth Conference, we have gained valuable follow-up data from key trials in early breast cancer, which have helped to clarify both the efficacy and safety and tolerability of the available strategies for endocrine therapy. Observations using endocrine agents in combination with other treatment have been similarly extended. More detailed analysis of preclinical models has improved our understanding of resistance to endocrine therapy, and efforts to explore these and other mechanisms in the clinic are now underway. All of this has and continues to contribute to a growing understanding of how to optimize the use of endocrine agents in both treating and preventing breast cancer.
Come
Steven E
SE
Breast Cancer Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Buzdar
Aman U
AU
Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
Ingle
James N
JN
Division of Medical Oncology, The Mayo Clinic, Rochester, Minnesota.
Johnston
Stephen R D
SRD
Department of Medicine, Royal Marsden Hospital, London, United Kingdom.
Brodie
Angela M
AM
Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland.
Coombes
R Charles
RC
Department of Medicine, Breast Unit, Imperial College School of Medicine, London, United Kingdom.
Miller
William R
WR
Breast Research Group, University of Edinburgh, Edinburgh, United Kingdom.
Pritchard
Kathleen I
KI
Clinical Trials and Epidemiology, University of Toronto at Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada.
Winer
Eric P
EP
Breast Oncology Center, Dana-Farber Cancer Institute, Boston, Massachusetts.
Zujewski
Jo Anne
JA
Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland.
Goss
Paul E
PE
Breast Cancer Research, Massachusetts General Cancer Center, Boston, Massachusetts.
D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000473:pathology; D009570:Nitriles / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole